Why is the Paradigm share price surging 5% today?

What’s driving the Paradigm share price higher on Thursday?

| More on:
A woman sits on a doctor's table as he examines her knee for osteoarthritis as part of Paradigm's study

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Paradigm shares zip 4.88% higher to $1.29 apiece
  • The company provided an update on its osteoarthritis study, advising the first subjects have been randomised and dosed 
  • The clinical trial is currently enrolling subjects at eight sites in Australia and 21 in the US 

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is racing higher during early afternoon trade on Thursday.

This comes after the biopharmaceutical company provided an update on its pivotal phase 3 clinical trial.

At the time of writing, the Paradigm share price is $1.29, up 4.88%.

What did Paradigm announce?

In today’s statement, Paradigm said the first subjects in the PARA_OA_002 clinical trial have been randomised and dosed in the United States.

The study’s objective is to evaluate the treatment of pentosan polysulfate sodium (PPS) on participants with knee osteoarthritis pain.

PPS, an injectable solution, aims to treat musculoskeletal disorders caused by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition.

The semi-synthetic drug is packaged as Zilosul. It has been shown to reduce pain, improve joint function, and prevent cartilage damaging joints.

Paradigm noted that the first subject randomisation occurred at Northwestern University in Chicago. It was conducted by lead investigator Dr Thomas Schnitzer.

The PARA_OA_002 study is currently enrolling subjects at eight sites in Australia and 21 sites in the US. In addition, locations in the United Kingdom and Europe are expected to be initiated in 2022.

Paradigm will evaluate study participants using WOMAC pain and WOMAC function at multiple time points from day 56 to day 168.

WOMAC is a widely-used health tool that assesses physical function, pain, and stiffness in patients with osteoarthritis. The self-administered instrument gives a score range for each of the three subclasses to indicate the patient’s health status.

Management commentary

Paradigm chief medical officer and interim CEO Dr Donna Skerrett said:

To have our first subjects randomised in the US is an important milestone in the OA clinical program.

The Paradigm clinical team has been working tirelessly to initiate and activate sites throughout the US and we are seeing a large number of subjects entering the screening phase throughout the US.

We look forward to continuing the strong momentum in the phase 3 program and reporting important recruitment milestones to our shareholders.

Paradigm share price snapshot

From November 2021, the Paradigm share price has been on a trending decline.

Paradigm shares hit an all-time low of 92.5 cents last month and have since moved in a sideways channel.

While falling 44% over the past 12 months, the bulk of these losses have come in 2022 — down 32%.

Based on valuation grounds, Paradigm commands a market capitalisation of roughly $286.19 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two researchers discussing results of a study with each other.
Healthcare Shares

Here’s how ASX 200 healthcare shares performed in June

Healthcare shares were a tad ill in June.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

What’s the outlook for the CSL share price in July?

We take a look at what the experts are saying about the biotech company's shares.

Read more »

Photo of a group of scientists cheering while working in a lab as the Race Oncology share price skyrockets today on positive study results
Healthcare Shares

Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Starphama share price lunges 5% on product relaunch

Early support for Starphama on Thursday has it off to a great start.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Why is the Paradigm share price rocketing 20% higher today?

The Paradigm share price is having a very strong day...

Read more »

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

Has CSL been growing its dividend?

Is the biotech giant still increasing its dividends in a post-COVID world?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why is the 4DMedical share price exploding 40% today?

4DMedical signed a three-year, nationwide contract with I-MED Radiology Network.

Read more »